The abstract is read at the publisher; the summary is JClub's.
In a prospective multicenter LAANTERN cohort of 787 brain tumor patients treated with Monteris NeuroBlate LITT, mortality was 0.25% and quality of life stayed stable up to 3 years.
- Why it matters: Clinicians need outcome data from real-world, multicenter experience to guide whether LITT can serve as a cytoreductive option while preserving function and minimizing complications.
- What they did: Patients with primary or metastatic brain tumors treated with LITT were prospectively followed across 25 US centers (2015–2023), with univariable and multivariable analyses of survival, adverse events, and functional status.
- The result: Adverse events occurred in 12.8% of patients (65.5% transient), and greater extent of ablation and smaller lesion size were linked to improved survival in high-grade glioma and recurrent metastases.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.